Program
HRS-9057
A development code. Also written as “HRS-9057 injection set” and “[14C]HRS-9057”.
Its studies are mostly in Heart Failure, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 32 open or running | phase 2since Nov 21, 2025 | Jun 28, 2024 | none ahead |
- Named in Jiangsu HengRui Medicine’s own pipeline as
HRS-9057
, phase 2, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 28, 2024First study: phase 1 study in Heart Failure With Volume OverloadFirst studyNCT06506994 · 25 enrolled · China
- Nov 21, 2025Phase 2 study in Fluid Retention Caused by Heart FailurePhase 2 reachedNCT07318103 · 153 planned · China
- Jun 23, 2026Phase 1 study in Fluid Retention Due to Heart FailureNCT07681479 · 6 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07681479Fluid Retention Due to Heart Failure · China | 1 | Active, not recruiting | Aug 11, 2026 | 6 |
| NCT07318103Fluid Retention Caused by Heart Failure · China | 2 | Recruiting | Sep 2026 | 153 |
| NCT06506994Heart Failure With Volume Overload · China | 1 | Completed | Oct 29, 2025 | 25 |
How it is read
Names in the registry
- “HRS-9057”, 2 entries
- “HRS-9057 injection set”, 1 entry
- “[14C]HRS-9057”, 1 entry
Codes read as this program: HRS9057.
Conditions, from the studies’ own filings
- Heart Failure, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.